In magnetic resonance imaging (MRI), cerebral blood volume (CBV) quantification is dependent on the MRI sequence and on the properties of the
contrast agents (CAs). By using the rapid steady-state T(1) method, we show the potential of
gadolinium per (3,6-anhydro)
alpha-cyclodextrin (
Gd-ACX), a new MRI paramagnetic CA (inclusion complex of
Gd(3+) with per (3,6-anhydro)-
alpha-cyclodextrin), for the CBV quantification in the presence of blood-brain barrier lesions. After biocompatibility and relaxivity experiments, in vivo experiments on rats were performed on a C6
tumor model with 0.05 mmol
Gd-ACX/kg (<1/10 of the median lethal dose) injected at a 25 mmol/L concentration, inducing neither nephrotoxicity nor
hemolysis. On T(1)-weighted images, a signal enhancement of 170% appeared in vessels after injection, but not in the
tumor (during the 1 h of observation), in contrast to the 90% signal enhancement obtained with
Gd-DOTA (a clinical MRI CA) injected at a T(1) isoefficient dose. This result shows the absence of
Gd-ACX extravasation into the
tumor tissue and its confinement to the vascular space. Fractional CBV values were found similar to
Gd-ACX and
Gd-DOTA in healthy brain tissue and in the contralateral hemisphere of
tumor-bearing rats, whereas only
Gd-ACX was appropriate for CBV quantification in
tumor regions.